PD-1/PD-L1抑制剂在非小细胞肺癌治疗中的应用进展

Abstract
Figure/Table
References (37)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Lung cancer is the most common malignant tumor in the world,and the mortality of lung cancer still is the first in all of tumors.Non-small cell lung cancer has a large proportion of the lung cancer.However,the current treatments for non-small cell lung cancer are limited and ineffective.Therefore,it is urgent to find a more effective treatment for non-small cell lung cancer.Programmed death-1 (PD-1)and its ligand,an important immunosuppressive molecule,whose ligand is PD-L1,has been discovered for over 20 years.In recent years,with the deepening research of programmed death-1(PD-1)and its ligand(PD-L1),the new treatment methods on the immune checkpoint has been gradually applied in clinical and gotten great achievements.Among them,the PD-1/PD-L1 inhibitors used to treat non-small cell lung cancer that have been significant clinical effect for the advanced patients.This paper reviewed the clinical effect and application of PD-1/PD-L1 inhibitors used commonly for non-small cell lung cancer.

Key words： Non-small cell lung cancer PD-1/PD-L1 inhibitors Clinical effect Clinical application

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GONG Jin
	LI Jian-qiang

Cite this article:

GONG Jin,LI Jian-qiang. Application of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer[J]. 中国当代医药, 2018, 25(9): 29-32.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I9/29

[13]	Motz GT，Coukos G.Deciphering and reversing tumor immune suppression[J].Immunity，2013，39（1）：61-73.
[19]	Joyce JA，Fearon DT.T cell exclusion，immune privilege，andthetumormicroenvironment[J].Science，2015，348（6230）：74-80.
[23]	Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer，2012，12（4）：252-264.
[3]	Torre LA，Bray F，Siegel RL，et al.Global cancer statistics，2012[J].CA Cancer J Clin，2015，65（2）： 87-108.
[12]	Chen DS，Mellman I.Oncology meets immunology： the cancer-immunity cycle[J].Immunity，2013，39（1）：1-10.
[1]	Chae YK，Pan A，Davis AA，et al.Recent advances and future strategies for immune-checkpoint inhibition in smallcell lung cancer[J].Clin Lung Cancer，2017，18（2）：132-140.
[2]	Hu Z，Chen X，Zhao Y，et al.Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer[J].J Clin Oncol，2010，28（10）：1721-1726.
[4]	Paramanathan A，Solomon B，Collins M，et al.Patients treated with platinum-doubletchemotherapy foradvanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation[J].Clin Lung Cancer，2013，14（5）：508-512.
[5]	Lu S，Cheng Y，Zhou CC，et al.Meta-analysis of first-line pemetrexed plus platinum treatment in compared to other platinum-based doublet regimens in elderly east asian patients with advanced nonsquamous non-small-cell lung cancer[J].Clin Lung Cancer，2016，17（5）：e103-e112.
[6]	He X，Wang J，Li Y.Efficacy and safety of docetaxel for advanced non-small-cell lung cancer：a meta-analysis of Phase Ⅲ randomized controlled trials[J].Onco Targets Ther，2015，8：2023-2031.
[7]	Fossella FV，DeVore R，Kerr RN，et al.Randomized phaseⅢtrial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy[J].J Clin Oncol，2004，22（1）：209.
[8]	Shepherd FA，Dancey J，Ramlau R，et al.Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy[J].J Clin Oncol，2000，18（10）：2095-2103.
[9]	Remon J，Chaput N，Planchard D.Predictive biomarkers for programmeddeath-1/programmeddeathligand immune checkpoint inhibitors in nonsmall cell lung cancer[J].Curr Opin Oncol，2016，28（2）：122-129.
[10]	La-Beck NM，Jean GW，Huynh C，et al.Immune checkpoint Inhibitors：new insights and current place in cancer therapy[J].Pharmacotherapy，2015，35（10）：963-976.
[11]	Shien K，Papadimitrakopoulou VA，Wistuba II.Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer[J].Lung Cancer，2016， 99：79-87.
[14]	Butte MJ，Keir ME，Phamduy TB，et al.Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses[J].Immunity，2007，27（1）：111-122.
[15]	Park JJ，Omiya R，Matsumura Y，et al.B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance[J].Blood，2010，116（8）：1291-1298.
[16]	Hegde PS，Karanikas V，Evers S.The Where，the When，and the How of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition[J].Clin Cancer Res，2016，22（8）：1865-1874.
[17]	Gajewski TF，Woo SR，Zha Y，et al.Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment[J].Curr Opin Immunol，2013，25（2）：268-276.
[18]	Woo SR，Corrales L，Gajewski TF.The STING pathway and the T cell-inflamed tumor microenvironment[J].Trends Immunol，2015，36（4）：250-256.
[20]	Gajewski TF.The Next Hurdle in Cancer Immunotherapy：Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment[J].Semin Oncol，2015，42（4）：663-671.
[21]	Herbst RS，Soria JC，Kowanetz M，et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J].Nature，2014，515（7528）：563-567.
[22]	Taube JM，Anders RA，Young GD，et al.Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape[J].Sci Transl Med，2012，4（127）：127ra37.
[24]	Kim ES，Hirsh V，Mok T，et al.Gefitinib versus docetaxel in previouslytreatednon-small-celllungcancer（INTEREST）：a randomised phase Ⅲ trial[J].Lancet，2008，372（9652）：1809-1818.
[25]	Hanna N，Shepherd FA，Fossella FV，et al.Randomized phaseⅢtrial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J].J Clin Oncol，2004，22（9）：1589-1597.
[26]	Wang C，Yu X，Wang W.A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advancednonsmallcelllungcancer[J].Medicine（Baltimore），2016，95（52）：e5539.
[27]	Brahmer J，Reckamp KL，Baas P，et al.Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer[J].N Engl J Med，2015，373（2）：123-135.
[28]	Borghaei H，Paz-Ares L，Horn L，et al.Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer[J].N Engl J Med，2015，373（17）：1627-1639.
[29]	Goldberg SB，Gettinger SN，Mahajan A，et al.Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases：early analysis of a non-randomised，open-label，phase 2 trial[J].Lancet Oncol，2016，17（7）： 976-983.
[30]	Garon EB，Rizvi NA，Hui R，et al.Pembrolizumab for the treatment of non-small-cell lung cancer[J].N Engl J Med，2015，372（21）： 2018-2028.
[31]	Topalian SL，Hodi FS，Brahmer JR，et al.Safety，activity，and immune correlates of anti-PD-1 antibody in cancer[J].N Engl J Med，2012，366（26）：2443-2454.
[32]	Wang A，Wang HY，Liu Y，et al.The prognostic value of PD-L1 expression for non-small cell lung cancer patients： a meta-analysis[J].Eur J Surg Oncol，2015，41（4）：450-456.
[33]	Tumeh PC，Harview CL，Yearley JH，et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance[J].Nature，2014，515（7528）：568-571.
[34]	Snyder A，Makarov V，Merghoub T，et al.Genetic basis for clinical response to CTLA-4 blockade in melanoma[J].N Engl J Med，2014，371（23）：2189-2199.
[35]	Markham A.Atezolizumab： First Global Approval[J].Drugs，2016，76（12）：1227-1232.
[36]	Fehrenbacher L，Spira A，Ballinger M，et al.Atezolizumab versus docetaxel for patients with previously treated nonsmall-cell lung cancer（POPLAR）：a multicentre，openlabel，phase 2 randomised controlled trial[J].Lancet，2016，387（10030）：1837-1846.
[37]	Hamanishi J，Mandai M，Matsumura N，et al.PD-1/PD-L1 blockade in cancer treatment：perspectives and issues[J].Int J Clin Oncol，2016，21（3）：462-473.